These Women Are Now Earning Almost as Much as Men
That women earn 77 cents for every dollar a man makes has been chronicled and discussed at length, but a new analysis by economists at the Federal Reserve Bank of New York finds a far smaller gap among recent grads.
The country’s youngest (ages 22 to 27) female workers earn roughly 97 cents on the dollar compared to their male peers, when controlling for major and field of employment. For many majors, they actually earn more.
Any early advantage disappears, however, once workers hit mid-career, with men earning 15 percent more than women across the board. Even in majors where women earned more during the early years of their careers, men earn more by age 35.
Related: 10 Worst States for Working Mothers
Researchers point to several potential reasons for the reversal, including possible gender discrimination and women’s tendency to scale back their careers to bear and raise children.
“Because raising a family often requires more flexible schedules, those with family responsibilities who have difficulty satisfying time-sensitive work demands may face lower wages in these types of jobs,” the authors write. “In fact, in jobs where such time demands are largely absent, and more flexibility is possible, the pay gap has been found to be much smaller.”
For some women, that means leaving the workforce entirely. The percentage of women age 25 to 54 who are working has fallen to 69 percent since peaking in 1999 at 74 percent, following a 60-year climb.
Top Reads From The Fiscal Times:
Chart of the Day: Boosting Corporate Tax Revenues
The leading candidates for the Democratic presidential nomination have all proposed increasing taxes on corporations, including raising income tax rates to levels ranging from 25% to 35%, up from the current 21% imposed by the Republican tax cuts in 2017. With Bernie Sanders leading the way at $3.9 trillion, here’s how much revenue the higher proposed corporate taxes, along with additional proposed surtaxes and reduced tax breaks, would generate over a decade, according to calculations by the right-leaning Tax Foundation, highlighted Wednesday by Bloomberg News.
Chart of the Day: Discretionary Spending Droops
The federal government’s total non-defense discretionary spending – which covers everything from education and national parks to veterans’ medical care and low-income housing assistance – equals 3.2% of GDP in 2020, near historic lows going back to 1962, according to an analysis this week from the Center on Budget and Policy Priorities.
Chart of the Week: Trump Adds $4.7 Trillion in Debt
The Committee for a Responsible Federal Budget estimated this week that President Trump has now signed legislation that will add a total of $4.7 trillion to the national debt between 2017 and 2029. Tax cuts and spending increases account for similar portions of the projected increase, though if the individual tax cuts in the 2017 Republican overhaul are extended beyond their current expiration date at the end of 2025, they would add another $1 trillion in debt through 2029.
Chart of the Day: The Long Decline in Interest Rates
Are interest rates destined to move higher, increasing the cost of private and public debt? While many experts believe that higher rates are all but inevitable, historian Paul Schmelzing argues that today’s low-interest environment is consistent with a long-term trend stretching back 600 years.
The chart “shows a clear historical downtrend, with rates falling about 1% every 60 years to near zero today,” says Bloomberg’s Aaron Brown. “Rates do tend to revert to a mean, but that mean seems to be declining.”
Chart of the Day: Drug Price Plans Compared
Lawmakers are considering three separate bills that are intended to reduce the cost of prescription drugs. Here’s an overview of the proposals, from a series of charts produced by the Kaiser Family Foundation this week. An interesting detail highlighted in another chart: 88% of voters – including 92% of Democrats and 85% of Republicans – want to give the government the power to negotiate prices with drug companies.
